Literature DB >> 20122736

Impact of diabetic retinopathy on vision-specific function.

Ecosse L Lamoureux1, E Shyong Tai, Julian Thumboo, Ryo Kawasaki, Seang-Mei Saw, Paul Mitchell, Tien Y Wong.   

Abstract

OBJECTIVE: To assess the influence of the spectrum of diabetic retinopathy (DR) on vision-specific function in an Asian population.
DESIGN: Population-based cross-sectional study. PARTICIPANTS: Persons aged 40 to 80 years of Malay ethnicity in Singapore.
METHODS: The Singapore Malay Eye Study was a population-based, cross-sectional study of 3280 Asian Malays (78.7% response rate). Five end points were considered: (1) any DR, (2) macular edema (ME), (3) clinically significant macular edema (CSME), (4) vision-threatening DR (VTDR), and (5) DR severity levels ranging from none to proliferative diabetic retinopathy (PDR). Vision function was assessed using the Vision-Specific Functioning Scale validated using Rasch analysis. MAIN OUTCOME MEASURES: Vision-specific functioning score.
RESULTS: Of 357 diabetic participants in the study, 23.2% had any DR, 5.6% had ME, 5.0% had CSME, 10.6% had VTDR, and 6.2% had PDR. In linear regression models adjusting for age, gender, stroke, diabetic risk factors, and socioeconomic factors, poorer vision-specific function was associated independently with any DR (beta, -0.21; P<0.05), ME (beta, -0.48; P<0.05), CSME (beta, -0.42; P<0.05), VTDR (beta, -0.64; P<0.05), and PDR (beta, -0.92; P<0.001). When controlling further for presenting visual acuity, VTDR (beta, -0.37; P = 0.01) and PDR (beta, -0.61; P = 0.002) were the only 2 DR categories independently associated with poorer vision-specific function and PDR. Persons with VTDR and PDR were 6 to 12 times more likely to report lower participation in daily living activities than those without these DR levels.
CONCLUSIONS: People with VTDR and PDR have substantial difficulty undertaking vision-specific daily activities. These findings reinforce the importance of preventative efforts targeted at the earliest DR stages to prevent progression to later stages of DR. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references. Copyright 2010 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20122736     DOI: 10.1016/j.ophtha.2009.09.035

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  19 in total

1.  Comparison of reading speed with 3 different log-scaled reading charts.

Authors:  Noor Halilah Buari; Ai-Hong Chen; Nuraini Musa
Journal:  J Optom       Date:  2014-01-28

2.  Prevalence of and risk factors for diabetic macular edema in the United States.

Authors:  Rohit Varma; Neil M Bressler; Quan V Doan; Michelle Gleeson; Mark Danese; Julie K Bower; Elizabeth Selvin; Chantal Dolan; Jennifer Fine; Shoshana Colman; Adam Turpcu
Journal:  JAMA Ophthalmol       Date:  2014-11       Impact factor: 7.389

3.  The impact of diabetic retinopathy on quality of life: qualitative findings from an item bank development project.

Authors:  Eva K Fenwick; Konrad Pesudovs; Jyoti Khadka; Mohamed Dirani; Gwyn Rees; Tien Y Wong; Ecosse L Lamoureux
Journal:  Qual Life Res       Date:  2012-12       Impact factor: 4.147

4.  The impact of the severity of vision loss on vision-specific functioning in a German outpatient population - an observational study.

Authors:  Robert P Finger; Eva Fenwick; Peggy Pei-Chia Chiang; Michael Petrak; Frank G Holz; Manjula Marella; Ecosse L Lamoureux
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-04-05       Impact factor: 3.117

5.  Different impact of early and late stages irreversible eye diseases on vision-specific quality of life domains.

Authors:  Preeti Gupta; Eva K Fenwick; Ryan E K Man; Alfred T L Gan; Charumathi Sabanayagam; Debra Quek; Chaoxu Qian; Chui Ming Gemmy Cheung; Ching-Yu Cheng; Ecosse L Lamoureux
Journal:  Sci Rep       Date:  2022-05-19       Impact factor: 4.996

6.  Vision related quality of life in patients with type 2 diabetes in the EUROCONDOR trial.

Authors:  Marina Trento; Olga Durando; Sonia Lavecchia; Lorena Charrier; Franco Cavallo; Miguel Angelo Costa; Cristina Hernández; Rafael Simó; Massimo Porta
Journal:  Endocrine       Date:  2016-09-14       Impact factor: 3.633

Review 7.  The relationship between diabetic retinopathy and psychosocial functioning: a systematic review.

Authors:  Krystal Khoo; Ryan E K Man; Gwyn Rees; Preeti Gupta; Ecosse L Lamoureux; Eva K Fenwick
Journal:  Qual Life Res       Date:  2019-03-16       Impact factor: 4.147

8.  The relative impact of vision impairment and cardiovascular disease on quality of life: the example of pseudoxanthoma elasticum.

Authors:  Robert P Finger; Eva Fenwick; Manjula Marella; Peter Charbel Issa; Hendrik P N Scholl; Frank G Holz; Ecosse L Lamoureux
Journal:  Health Qual Life Outcomes       Date:  2011-12-12       Impact factor: 3.186

9.  Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective.

Authors:  Stephane A Régnier; William Malcolm; Jennifer Haig; Weiguang Xue
Journal:  Clinicoecon Outcomes Res       Date:  2015-05-06

10.  Attenuated levels of pro-inflammatory markers in diabetic retinopathy patients undergoing treatment with antihyperglycemic and antihypertensive drugs.

Authors:  Zhi Xiang Ng; Kek Heng Chua; Iqbal Tajunisah; Rokiah Pendek; Umah Rani Kuppusamy
Journal:  Clinics (Sao Paulo)       Date:  2013       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.